- About WAGR Syndrome
- News & Events
- Get Involved
- About Us
Kelly Trout, BSN, RN
Director, Research and Medical Advocacy
International WAGR Syndrome Association
In early November 2019, more than three dozen scientists, clinicians, and patient representatives met on the campus of the University of Virginia to share their work on aniridia-related research and initiatives.
The meeting was unusual in several ways. Instead of a large conference, the small number of participants allowed for in-depth group discussion. Instead of focusing on a single area of research, the agenda spanned a variety of disciplines, which gave participants fresh context and new ideas for their own work. The meeting also included a number of patients and patient advocacy group representatives, who not only learned more about the research process but also contributed their unique perspectives to the discussion. The IWSA was represented at this conference by Shari Krantz, Executive Director, and Kelly Trout, Board Chair and Director of Research and Medical Advocacy.
The following notes were taken at the meeting. Please note that many of the presentations involved “basic science” research on how the eye develops before and after birth, often using animal models, rather than studies involving patients. While basic science is the crucial first step toward discovering new treatments, it is highly technical. The notes below are from the presentations of particular interest to patients.
Introduction: “Looking back and peering forward”
Veronica van Heyningen, University College, London
Dr van Heyningen spoke about how the work of many researchers is broadening our understanding of the many different types of aniridia-related gene mutations. This work has led to current advances, such as the use of iPSC (induced pluripotent stem cells) to study the cornea problems associated with aniridia. It has also led to important new questions about aniridia-related problems with sleep, obesity, and neurological (brain) issues. In the future, this work could lead to gene therapies, improvements in surgical techniques, and perhaps even to technology such as an “artificial retina.”
In 1992, Veronica van Heyningen was instrumental in the discovery that Pax6 is the primary gene involved with aniridia. Although semi-retired now, Veronica van Heyningen continues to work on several aniridia-related projects, and serves as Patron of Aniridia Network UK
“Phenotype/Genotype correlation in aniridia”
Dominique Bremond-Gignac, Universite Paris V Descartes, Hopital Universitaire Necker, Paris
Visual impairment in aniridia can occur from various mechanisms, such as:
Dr. Bremond-Gignac noted that limbal cell insufficiency as the sole cause of aniridic keratopathy has become controversial. Many researchers are now considering that keratopathy in aniridia is likely the result of multiple problems, including abnormalities in the tear film of patients with aniridia.
Dr. Bremond-Gignac is the Chairperson of the Scientific Committee of Aniridia Europe. Aniridia Europe is a member of ERN-EYE, a European Reference Network dedicated to Rare Eye Diseases: https://www.ern-eye.eu/
“Using genomics to elucidate mechanisms of acquired ocular disease in aniridia” Melinda Duncan, University of Delaware
Dr. Duncan discussed cataract and cornea problems in patients with aniridia. Her work investigates why these problems occur. One clue is that the Pax6 gene is expressed (makes a protein) throughout life. In people with aniridia, only 50% of this protein is made. In the lens, Pax6 helps lens cells “remember” to be lens cells. Without it, lens cells appear to make molecules that cause them to act more like scar cells. These molecules may also sensitize the rest of the eye to form scar tissue.
“Genotype-phenotype studies of aniridia-associated keratopathy in European cohorts”
Neil Lagali, Linköping University, Sweden
More than 400 unique Pax6 mutations have been reported. There are also additional genes involved in some cases of aniridia. This work involved assessment of 92 eyes for aniridia-associated keratopathy. The researchers graded keratopathy on a scale of 0-4, and compared clinical observations with the patient’s specific mutation.
In this study:
The researchers concluded that aniridia-associated keratopathy is likely a condition with multiple subtypes. Some mutation types were clearly associated with more severe presentation and progression. Additional research is needed to help classify where each mutation type falls on the keratopathy spectrum. This research could help doctors diagnose and treat different subtypes of keratopathy and help with future clinical trials.
“Anterior Chamber Angle in Aniridia”
Peter Netland, University of Virginia
In the past, it was thought that progressive closure of the anterior chamber angle was responsible for the development of glaucoma in patients with aniridia. This study examined 43 patients (86 eyes) using high-resolution anterior segment optical coherence tomography (OCT) or clinical gonioscopy, or both.
Update on the Ataluren clinical trial:
“Clinical conundrums in interpreting results of molecular genetic testing”
Kevin Gregory-Evans, University of British Columbia, Eye Care Centre
Dr Gregory-Evans discussed the difficulties involved in providing a diagnosis for patients whose genetic testing results are highly complex. A lively discussion between clinicians and patients/patient advocacy group representatives followed.
Main clinical takeaways for patients:
“Developmental gene profiling as a mechanism for identifying genes for uveal coloboma”
Brian Brooks, National Institutes of Health, National Eye Institute
“Building the retina one cell at a time”
Seth Blackshaw, Johns Hopkins University
“Development of a cell-based approach to treat genetic keratopathy”
Jim Lauderdale, University of Georgia
“Therapeutic approaches targeting anterior chamber defects in the Pax6Sey/+ model of aniridia”
Cheryl Gregory-Evans, University of British Columbia, Eye Care Centre
“The role of Pax6 and Meis transcription factors in vertebrate eye development”
Zbynek Kozmik, Academy of Sciences of the Czech Republic
“Visible light optical coherence tomography: new capabilities and new opportunities”
Hao Zhang, Northwestern University
“In vivo imaging of the retinal nerve fiber layer in mice”
Xiaorong Liu, University of Virginia
“Novel genes and pathways important to the healthy and keratoconic cornea”
Shukti Chakravarti, NYU Langone Health
“The role of MAB21L proteins in eye development and disease”
David FitzPatrick, University of Edinburgh, MRC Institute of Genetics and Molecular Medicine
“Retinal pigmented epithelium development from the perspective of transcription factors and cis-regulatory elements”
Ruth Ashery-Padan, Tel Aviv University
“Pax6 and gene regulatory networks of crystallin gene expression”
Ales Cvekl, Albert Einstein College of Medicine
“Repurposing MEK inhibitors for therapeutically enhancing Pax6 expression in congenital aniridia.”
Ali Djalilian, University of Illinois College of Medicine
“Development of a sensitive and selective assay to measure PAX6 protein using impression cytology”
Marla Weetall, PTC Therapeutics
“The role of Six3 in the gene hierarchy regulating eye formation and its contribution to lens formation and retinal patterning”
Rob Grainger, University of Virginia
“Gene therapy for genetic retinal disorders in mice and (hu)man”
Arlene Drack, University of Iowa
“Ocular Surface and Aniridia”
Marc Odrich, University of Virginia